Prevalence and Determinants of Female Sexual Dysfunction, and Its Association With Neurotrophic Biomarkers in Gynaecological Cancer Survivors: A Cross-Sectional Study

Cancer Control · Published 2026-06-01 · DOI 10.1177/10732748261465284

Free full text

Authors (12)

Nilanchali Singh, Shalini Singh, Rizwana Quraishi, DN Sharma, Zakiya Zakiya, Seema Singhal, Jyoti Meena, Shivangi Mangal, Garg Himakshi, Rajesh Kumari, Anju Singh, Neena Malhotra

Abstract

Introduction Female sexual dysfunction (FSD) in any gynaecological cancer survivor is one aspect of female functioning that is neglected in survivorship care. Therefore, their actual prevalence is far from known to the treating physician. This study aimed to evaluate the prevalence of sexual dysfunction in gynaecological cancer survivors, determine its risk factors, and correlate sexual dysfunction with serum neurotropic factors. Methods This was a cross-sectional, observational study among 200 gynaecological cancer survivors who are sexually active, conducted in the gynaecological cancer clinic at a tertiary care centre. Sexual function was assessed using the Hindi-validated Female Sexual Function Index (FSFI), and serum brain-derived neurotrophic factor (BDNF), substance P, and neuropeptide Y (NPY) were measured by ELISA. The correlation between these biomarkers, with domains and subdomains of the female sexual function index, was explored. Results In this cohort of 200 gynaecological cancer survivors, 189 (94.5%) women had FSD (FSFI <26.55). Age was the only independent clinical predictor of FSD in multivariable analysis (p = 0.02), while cancer site, stage, treatment modality, and menopausal status were not significant in this cohort. Overall biomarker levels did not differ between women with and without FSD. However, subdomain analysis showed high dysfunction rates in lubrication, orgasm, pain, and arousal, with significant biomarker differences for substance P and NPY in several dysfunctional subdomains. Conclusions FSD was highly prevalent in gynaecological cancer survivors. While overall biomarker differences were not significant, subdomain-specific associations suggest that substance P and NPY may have a role in domain-level sexual dysfunction and merit further study.

Abstract from DOAJ. Public domain (CC0 1.0).

Read the article at the publisher →

Publication details

Year
2026

Citation

Singh, N., Singh, S., Quraishi, R., et al. (2026). Prevalence and Determinants of Female Sexual Dysfunction, and Its Association With Neurotrophic Biomarkers in Gynaecological Cancer Survivors: A Cross-Sectional Study. Cancer Control. https://doi.org/10.1177/10732748261465284

Related articles